pharma mar sa - PHMMF

PHMMF

Close Chg Chg %
86.36 -0.10 -0.12%

Pre-Market

86.26

-0.10 (0.12%)

Volume: 216.00

Last Updated:

Dec 10, 2025, 11:21 AM EDT

Company Overview: pharma mar sa - PHMMF

PHMMF Key Data

Open

$86.26

Day Range

86.26 - 86.26

52 Week Range

80.91 - 110.40

Market Cap

$1.56B

Shares Outstanding

17.21M

Public Float

12.00M

Beta

0.42

Rev. Per Employee

N/A

P/E Ratio

42.52

EPS

$2.13

Yield

94.18%

Dividend

$0.93

EX-DIVIDEND DATE

Jun 25, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

20.67

 

PHMMF Performance

No Data Available

PHMMF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About pharma mar sa - PHMMF

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.

PHMMF At a Glance

Pharma Mar SA
Avenida de los Reyes, 1
Colmenar Viejo, Madrid 28770
Phone 34-91-846-60-00 Revenue 189.14M
Industry Pharmaceuticals: Other Net Income 28.26M
Sector Health Technology 2024 Sales Growth 10.619%
Fiscal Year-end 12 / 2025 Employees N/A
View SEC Filings

PHMMF Valuation

P/E Current 42.518
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 51.287
Price to Sales Ratio 7.673
Price to Book Ratio 6.731
Price to Cash Flow Ratio 222.60
Enterprise Value to EBITDA 133.087
Enterprise Value to Sales 7.105
Total Debt to Enterprise Value 0.039

PHMMF Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 4.348
Total Asset Turnover 0.512

PHMMF Liquidity

Current Ratio 3.026
Quick Ratio 2.398
Cash Ratio 1.869

PHMMF Profitability

Gross Margin 91.448
Operating Margin 1.466
Pretax Margin 6.854
Net Margin 14.941
Return on Assets 7.643
Return on Equity 13.161
Return on Total Capital 10.528
Return on Invested Capital 11.214

PHMMF Capital Structure

Total Debt to Total Equity 24.414
Total Debt to Total Capital 19.623
Total Debt to Total Assets 14.531
Long-Term Debt to Equity 19.787
Long-Term Debt to Total Capital 15.904
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pharma Mar Sa - PHMMF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
271.66M 206.35M 170.98M 189.14M
Sales Growth
-11.73% -24.04% -17.14% +10.62%
Cost of Goods Sold (COGS) incl D&A
23.41M 18.18M 14.37M 16.18M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
6.60M 6.20M 6.22M 7.32M
Depreciation
5.39M 5.14M 5.11M 6.19M
Amortization of Intangibles
1.21M 1.06M 1.12M 1.14M
COGS Growth
+8.72% -22.34% -20.96% +12.56%
Gross Income
248.24M 188.17M 156.61M 172.96M
Gross Income Growth
-13.27% -24.20% -16.77% +10.44%
Gross Profit Margin
+91.38% +91.19% +91.60% +91.45%
2021 2022 2023 2024 5-year trend
SG&A Expense
128.29M 129.68M 148.58M 156.16M
Research & Development
83.10M 85.53M 104.87M 107.84M
Other SG&A
45.19M 44.15M 43.71M 48.33M
SGA Growth
+33.35% +1.08% +14.57% +5.11%
Other Operating Expense
13.13M 14.01M 13.82M 14.03M
Unusual Expense
(329.77K) 1.94M (292.98K) (234.73K)
EBIT after Unusual Expense
107.15M 42.53M (5.49M) 3.01M
Non Operating Income/Expense
9.28M 5.99M 4.19M 12.63M
Non-Operating Interest Income
437.33K 919.60K 4.44M 6.14M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.99M 2.50M 2.61M 2.67M
Interest Expense Growth
+11.95% -37.37% +4.60% +2.25%
Gross Interest Expense
3.99M 2.50M 2.61M 2.67M
Interest Capitalized
- - - -
-
Pretax Income
112.44M 46.02M (3.92M) 12.96M
Pretax Income Growth
-32.26% -59.07% -108.51% +430.98%
Pretax Margin
+41.39% +22.30% -2.29% +6.85%
Income Tax
2.68M (5.85M) (5.15M) (15.30M)
Income Tax - Current - Domestic
(2.73M) (2.48M) (4.14M) 435.92K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
5.41M (3.37M) (1.00M) (15.73M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
109.76M 51.87M 1.23M 28.26M
Minority Interest Expense
- - - -
-
Net Income
109.76M 51.87M 1.23M 28.26M
Net Income Growth
-29.86% -52.74% -97.63% +2,198.94%
Net Margin Growth
+40.40% +25.14% +0.72% +14.94%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
109.76M 51.87M 1.23M 28.26M
Preferred Dividends
- - - -
-
Net Income Available to Common
109.76M 51.87M 1.23M 28.26M
EPS (Basic)
6.074 2.8738 0.0687 1.6112
EPS (Basic) Growth
-28.99% -52.69% -97.61% +2,245.27%
Basic Shares Outstanding
18.07M 18.05M 17.90M 17.54M
EPS (Diluted)
6.069 2.8717 0.0686 1.6091
EPS (Diluted) Growth
-28.93% -52.68% -97.61% +2,245.63%
Diluted Shares Outstanding
18.09M 18.06M 17.92M 17.56M
EBITDA
113.42M 50.67M 438.93K 10.10M
EBITDA Growth
-38.84% -55.32% -99.13% +2,200.50%
EBITDA Margin
+41.75% +24.56% +0.26% +5.34%

Pharma Mar Sa in the News